The value of the human epidermal growth factor receptor-2 (HER2) as a prognostic marker.

The prognosis for patients with breast cancer is determined by well-established pathological features associated with biological aggressiveness, histological grade, tumour size and nodal involvement. These remain the key determinants, despite the identification of numerous other potential biological markers. The use of prognostic indices, such as the Nottingham Prognostic Index (NPI), which combines and weights these factors, enables clinicians to predict outcome with a certain amount of accuracy. Approximately 20-30% of breast cancers express very high quantities of the human epidermal growth factor receptor-2 (HER2) protein and this is almost always associated with gene amplification. With the use of sensitive techniques, such as the radio-immunohistochemical method (rIHC) described herein, to quantify HER2 protein levels, up to a further 50% of such cancers will be found to express the HER2 receptor at least 4-fold higher than normal breast cells. Adding HER2 expression to the NPI helps to determine more accurately the prognosis for individual patients, particularly those with node-negative disease. Overall, the main value of HER2 measurement is likely to be in the prediction of response to therapies targeting the HER2 gene and protein.